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Abstract: New strategies to efficiently treat bacterial infec-
tions are crucial to circumvent the increase of resistant
strains and to mitigate side effects during treatment. Skin
and soft tissue infections represent one of the areas suf-
fering the most from these resistant strains. We developed
a new drug delivery system composed of the green algae,
Chlamydomonas reinhardtii, which is generally recognized
as safe, to target specifically skin diseases. A two-step
functionalization strategy was used to chemically modify
the algae with the antibiotic vancomycin. Chlamydomonas
reinhardtii was found to mask vancomycin and the inser-
tion of a photocleavable linker was used for the release of
the antibiotic. This living drug carrier was evaluated in
presence of Bacillus subtilis and, only upon UVA1-mediat-
ed release, growth inhibition of bacteria was observed.
These results represent one of the first examples of a
living organism used as a drug delivery system for the re-
lease of an antibiotic by UVA1-irradiation.
Due to the steady increase in the number of pathogenic bacte-
ria, including resistant strains,[1] there is an urgent need for the
development of new treatment strategies.[2] One of the most
important burdens to our health system is the treatment of
skin and soft tissue infections (SSTIs).[3] This disease affected up
to 1 million people in the United States alone in 2010.[4] The
most identified pathogen responsible for SSTI is Staphylococcus
aureus (S. aureus) and the microorganism was found to be me-
thicillin resistant (MRSA) in around half of the cases.[5] Fortu-
nately, these strains are still sensitive to last resort antibiotics
such as vancomycin, however, resistant mechanisms have al-
ready been identified.[6] Several approaches have been devel-
oped during the last decades in order to mitigate the develop-
ment of resistant strains by using drug delivery systems. The
advantage of such methodology is to efficiently release the an-
tibiotic at a precise time and location, thereby avoiding the de-
velopment of resistance and lowering the side effects of the
drugs.[7]
Currently, the main technology relies on the use of nanopar-
ticles (NPs), so-called “nanoantibiotics”, which can exhibit in-
trinsic antibacterial activity and can be further functionalized.[8]
These systems can be classified in six main categories based
on their composition:[9] An ideal drug delivery system would
control the release of the drug using an external stimulus.[7, 10]
This strategy was applied for the release of vancomycin by
well-designed NP systems using different stimuli, such as bac-
terial enzymes,[11] pH variation,[12] presence of bacterial cells,[13]
near-infrared light,[14] and temperature change.[15] The main
issue that was raised with the use of NPs is their potential toxi-
city,[8b, 16] burst effects,[17] or limited drug loadings.[18] Moreover,
exposure to nanoparticles may promote bacterial resistance in
certain situations.[19]
In this study, we aimed to develop a new drug delivery
system that is optimized for bacterial skin infections with trig-
gered release of antibiotics. We selected living cells as a carrier
based on promising results observed for such systems.[20] In
particular the algae Chlamydomonas reinhardtii (C. reinhardtii)
would represent the ideal candidate carrier due to its property
to be biodegradable,[21] generally recognized as safe (GRAS),[22]
not triggering an immune response,[23] antibiotic producer,[24]
and for its potential for further genetic modifications.[25] Fur-
thermore, promising results have already been demonstrated
for chemical surface engineering of this organism.[26]
In this study, we aimed to functionalize the surface of C. rein-
hardtii with an antibiotic and to release the active compound
by light irradiation. This specific release method was chosen
due to the fact that phototherapy already showed promising
results for skin treatment.[27] As a proof of concept, vancomycin
was selected as the antibiotic (Figure 1).
The new drug delivery system consists of living functional-
ized algae, which possess the advantage to produce beneficial
compounds such as O2 and could be genetically engineered.
In the first part of our study, we focused on a methodology to
attach vancomycin covalently on the surface of C. reinhardtii
and we hypothesized that the algae would mask the antibiotic
from the bacteria. The synthetic route should include bioor-
thogonal reactions and the chemical steps should not affect
the viability of C. reinhardtii. We decided to combine our re-
ported strategy using N-hydroxysuccinimide (NHS) ester for
the functionalization of the algae[26c] with the Cu free azide-
alkyne cycloaddition used by Cooper and co-workers (Fig-
ure 2A).[28] This strategy would provide the bioorthogonal
anchor dibenzocyclooctyne (DBCO) 1 on the algae surface and
we hypothesized that the Cu free azide-alkyne cycloaddition
would not affect the viability of the organism.
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We started our investigation with the surface functionaliza-
tion of C. reinhardtii using a DBCO anchor. The algae were in-
cubated with the NHS-PEG4-DBCO (1) for one hour and the
cells were centrifuged and washed with PBS buffer. The label-
ing strategy was evaluated using an azide-containing fluores-
cent derivatives of vancomycin, which was synthesized and at-
tached covalently using a three ethylene glycol (PEG) chain as
linker. We were pleased to observe by microscope experiments
the presence of the labelled antibiotic on the surface of the or-
ganism (see Supporting Information).
The photocaging properties were investigated in the next
experiment. Recently, the research group of Cooper and collab-
orators demonstrated that the immobilization of vancomycin
derivative (VancPEG3N3 (2)) on the surface of magnetic particles
via NHS-PEG4-DBCO linker (1) improved the activity of the anti-
biotic toward the sensitive S. aureus and also against resistant
strains.[28] Taking advantage of this result, the C. reinhardtii sur-
face was modified using vancomycin azide derivatives possess-
ing a PEG3 linker chain. Additionally, to investigate the chain
size of the linker to the effectiveness of the photocaging, Van-
comycin derivatives with 35 and approximately 100 ehtylene
glycol units (VancPEG35N3 (3), VancPEG100N3 (4)) were also syn-
thesized. Using our labeling strategy (Figure 2A), the com-
pounds were attached on the surface of the algae and the an-
tibacterial activity against Bacillus subtilis (B. subtilis) of the con-
struct was investigated. As expected, independent of the PEG
chain size, the modified C. reinhardtii did not exhibit antibacte-
rial activity (see the Supporting Information). Similar effects
were observed by the group of Simard, where the nanoparticle
size influenced the efficiency of vancomycin[29] and by the
groups of Wong and Choi during their study of photocaging
properties of ciprofloxacin attached to NPs.[30]
The next step focused on the development of a method to
control the release of the active agent from the carrier by an
external stimulus. An ideal photocleavable linker would absorb
Figure 1. Design of a novel drug delivery system to potentially treat SSTIs.
The carrier is the green algae C. reinhardtii selected as a generally recognized
as safe organism (GRAS),[22] biodegradable,[21] and not immunogenic.[23] A
photocleavable linker was chosen as the controlled release system of choice
due to its compatibility with existing phototherapy using UV light to treat
bacterial skin infection.
Figure 2. A) General two-step procedure for the algal surface modification using dibenzocyclooctyne and vancomycin azide derivatives. B) Representation of
vancomycin derivatives C) Photolysis reaction of VancphotoN3 (5) and its degradation product VancNH2 (6).




the light above 340 nm in order to be compatible with existing
skin phototherapy and not affecting C. reinhardtii viability. It
has been shown that treatment with ultraviolet A1 light (UVA1,
340–400 nm), did not trigger serious side effects and was effec-
tive against several skin diseases.[27,31] Disadvantages of this ap-
proach include (1) duration of treatment resulting in undesired
UV damage, and (2) the treatment has to be repeated several
times in order to be efficient.[32] To increase the efficacy of this
method, a photocleavable linker o-nitrobenzyl (o-NB) was se-
lected for its favorable absorption properties at 365 nm[33] and
was attached to vancomycin, via a three step strategy, to
obtain the vancomycin derivative (VancphotoN3 (5)). The first
step included the synthesis of the modified linker using the
amino PEG3 azide and 4-{4-[1-(9-Fluorenylmethyloxycarbonyl-
amino)ethyl]-2-methoxy-5-nitrophenoxy}butanoic acid. A Fmoc
deprotection following by the coupling with vancomycin in
presence of propylphosphonic anhydride (T3P) furnished the
desired product 5. Using our photocaged vancomycin 5, we
optimized the parameters of the labeling strategy. An increase
in the concentration of the DBCO linker by a factor of 4 raised
the labeling efficiency by approximately 20% (see Supporting
Information). The data obtained from these screens indicated
that using a VancphotoN3 (5) concentration of 5 mm and
100 mm of DBCO linker would be ideal for the modification of
the algae surface. The impact of the labeling strategy was eval-
uated on the viability of C. reinhardtii and we were pleased to
observe that the algae were not significantly affected by the
treatment (see Supporting Information).
To test the best photocleavable conditions, the amide deriv-
ative (VancNH2 (6)), resulting from the UVA1 cleavage of 5 (Fig-
ure 2C), was synthesized. Pleasingly, the biological activity of 6
was evaluated against B. subtilis and an encouraging minimal
inhibitory concentration (MIC) value of 0.06 mgmL@1 was deter-
mined (MIC of vancomycin: 0.125–0.25 mgmL@1). The conver-
sion from 5 to 6 by UVA1 light was determined via analyzing
the formation of the amide derivative 6 by UHPLC-MS meas-
urements in SIM mode (applied for the limit detection units)
using the synthetic compound as analytic standard. The irradi-
ation time was varied from 5 min to 15 min and the results
demonstrate that the concentration of the product increased
quickly and reached a maximum of 70% conversion after
5 min. The experiment was also tested in the presence of the
algae and a slight decrease of 10% in conversion was ob-
served (see Supporting Information). Based on these results,
5 min of UVA1-irradiation was chosen in order to preserve
algal viability. Using our optimal conditions, we covalently at-
tached construct 5 on the surface of the algae. Gratefully, after
5 min of UVA1-irradiation, a conversion of 20–25% of VancNH2
(5) was determined by UHPLC-MS measurements. The lower
yield, in comparison of the previous results, could be explained
by the proximity of vancomycin with the surface of the algae,
which could mask the linker from the light, retention of the
compound on the algae, or other factors. Interestingly, the
measured concentration (0.27 mgmL@1) of released VancNH2 (6)
is higher that the MIC value determined for 6 (0.06 mgmL@1)
and, consequently, would be sufficient to inhibit the growth of
B. subtilis (See Supporting Information). Furthermore, the
device selected for our UVA1 experiments, SI MA 032 from
Sina, is commercially available and inexpensive, is compatible
with other skin treatments (365 m) and is already used in the
cosmetic industry.
We were ready to investigate our system with the optimized
parameters and to determine the antibacterial activity on
B. subtilis of the modified algae before and after photocleav-
age. The algae were modified with VancphotoN3 (5, 5 mm) ac-
cording to the general protocol (Figure 2A) and were added to
a suspension of B. subtilis in 24-well plates. The system was ir-
radiated at 365 nm for 5 min. As a negative control experi-
ment, the modified algae were added after irradiation, and
after 12 h of incubation, the bacterial growth inhibition was
found only in the wells, which were irradiated in presence of
the modified algae (Figure 3). Pleasingly, the antibacterial activ-
ity was even observed in the system using a loading concen-
tration of VancphotoN3 (5) as low as 2.5 mm (see Supporting In-
formation). Furthermore, control experiments provided evi-
dence that neither VancphotoN3 (5) incubated with algae nor
the by-products after UVA1-irradiation significantly influenced
bacterial growth (see Supporting Information). The effect of
UVA1-irradiation on the algae was also tested and we did not
observe a significant decrease on cell viability (see Supporting
Information).
In order to demonstrate the advantage of this method, the
experiment using the modified algae with VancphotoN3 (5)
was repeated with an UVA1-irradiation step during the expo-
Figure 3. B. subtilis growth curves in the presence of functionalized algae
with VancphotoN3 (5, red curve) or in the absence of the algae as control ex-
periment (black curve). DBCO (1) concentration for the algae functionaliza-
tion was 100 mm and VancphotoN3 (5) was 5 mm. A) The samples were UVA1-
irradiated at a wavelength of 365 nm for 5 min. B) The samples were not ex-
posed to a UVA1 irradiation. C) The samples were UVA1-irradiated at a wave-
length of 365 nm for 5 min after 5 h of incubation. D) The functionalized
algae with VancphotoN3, were UVA1-irradiated at a wavelength of 365 nm
for 5 min, the algae cells were washed with PBS (3x) and the resulting cells
were incubated with B. subtilis. The growth curve of this experiment is dis-
played in blue. Data points adjusted to initial value 0.1 and represent mean
value :SD (n=3).




nential phase of the bacterial growth (Figure 3C). After incu-
bating the bacteria with the modified algae for 5 h in 24-well
plates, the system was UVA1-irradiated at 365 nm for 5 min
and the bacterial concentration was analyzed. A clear inhibi-
tion of the bacterial growth was observed for the samples con-
taining the modified algae compare to the negative control.
However, a lower loading concentration (2.5 mm) of 5 was not
sufficient, in this case, to inhibit bacterial growth (see Support-
ing Information). This might be explained by a higher concen-
tration of bacteria present after several hours of incubation.
In summary, a new and efficient drug delivery system was
designed and optimized. The developed system relies on the
green algae C. reinhardtii, an organism generally recognized as
safe.[22] In a first step, the chemical anchor DBCO was installed
providing a platform for the functionalization of the C. rein-
hardtii surface. Vancomycin was covalently attached, and, as
predicted, no antibacterial activity of the system was observed.
Consequently, using a photocleavable linker, we were able to
release the active vancomycin derivative, VancNH2 (6), in a
highly-controlled manner by light irradiation. The release ex-
periments could even be performed in presence of B. subtilis
and a strong growth inhibition by released antibiotics was ob-
served after UV-irradiation (365 nm, 5 min). Control experi-
ments demonstrated that the bacteria were not affected by
the UVA1-irradiation step. Potentially, the controlled release
strategy is compatible with therapeutic approaches to threat
SSTIs and other skin treatments, such as phototherapy using
UVA1. Furthermore, we could demonstrate that the functionali-
zation steps and the UVA1 irradiation did not affect significant-
ly the cell viability of C. reinhardtii. In summary, these results
represent one of the first reports where a living organism was
chemically modified and used for the controlled release of an
antibiotic. Based on this living organism, the system could be
further modified either by chemistry or by biotechnology, har-
vesting the advantages of both fields. This methodology
opens new ways for drug delivery and might be critical in the
development of strategies for skin and soft tissue infections,
Experimental Section
The experimental procedures and the characterization of the com-
pounds are found in the Supporting Information.
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